Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 75
Selected: 0
NCT IDTitle
NCT04824937Telaglenastat + Talazoparib In Prostate Cancer
NCT03007732Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
NCT02499835Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
NCT03805594177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05766371Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
NCT01950143Effect of Sulforaphane on Prostate CAncer PrEvention
NCT02881242Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
NCT02582697Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT02269982Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
NCT06040125Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
NCT05702619Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
NCT05327465Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
NCT02025413Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
NCT07002320Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
NCT00953576Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
NCT02445976Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
NCT02985021Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
NCT05078151Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer
NCT02135484Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
NCT06200974Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
NCT0471672568Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
NCT03492424Ablative Therapy in the Management of Prostate Cancer
NCT00744549Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
NCT06449664Training for Men Undergoing Androgen Deprivation Therapy.
NCT05113537Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT07050433COMPASS Study for Metastatic Castration-resistant Prostate Cancer
NCT05435495Mechanisms of Resistance to PSMA Radioligand Therapy
NCT05041504A Web-based Peer Navigation Program for Men With Prostate Cancer
NCT04090528pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT01961713Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
NCT03031821Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
NCT02478125Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
NCT02300324The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS)
NCT06059118Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT04343885In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
NCT02080650Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
NCT02677376Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
NCT02159690A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
NCT00651222Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy
NCT05320406RElugolix VErsus LeUprolide Cardiac Trial
NCT03957252Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
NCT02856100Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
NCT03440554Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization
NCT05918263Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
NCT05445609Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT06424275Prostate Cancer Awareness and Initiative for Screening in the European Union
NCT02735252PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
NCT03644303Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
NCT01417182Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
NCT01289067Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca